RNA Analysis Market Size to Worth Around USD 42.35 Bn by 2030

According to Nova one advisor, the global RNA Analysis market size was estimated at USD 11.19 billion in 2022 and is projected to hit around USD 42.35 billion by 2030, growing at a CAGR of 16.62% during the forecast period 2022 to 2030.

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7592

Key Takeaways:

• Real-Time- PCR (qPCR) accounted for the major market share in the technology segment in 2021 and is said to continue the trend during the forecast period owing to the increasing use of PCR for COVID-19 diagnostic across the globe
• The transcriptome sequencing technology is estimated to register a significant CAGR during the forecast period owing to factors, such as advancements in sequencing technology and growing acceptance of NGS technology
• The kits and reagents segment accounted for the highest revenue share in 2021 owing to a high utilization rate of consumables during transcriptomic studies
• The infectious diseases and pathogenesis segment accounted for the largest share in 2021 and is anticipated to have a similar trend during the forecasted period
• The increasing prevalence of the infectious disease is the major factor driving the segment growth
• Government institutes & academic centers dominated the end-user segment as the increasing number of institutes and centers leveraged high throughput technologies for the effective and efficient process of ribonucleic acid analysis

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7592

Report Scope of the RNA Analysis Market

Transcriptomics is one of the most advanced fields in the post-genomic period. Technological advancements in this industry can be attributed to the increasing applications of transcriptome sequencing in life science for capturing polyadenylated RNA. With the expansion of next-generation high-throughput sequencing technology, the analysis of transcriptomes has been gradually improving the understanding of the regulatory network of RNA-based genes. For instance, in July 2021, the Lithuanian team is developing a droplet-based technique for simultaneous mRNA and microRNA capture and sequencing in a single cell.

The research is backed by the European Union with a USD174,000 Horizon 2020 research grant. Moreover, in May 2022, CD Genomics launched the Digital RNA sequencing technology, which is an NGS-based method that excludes sequence-dependent PCR. Such initiatives are anticipated to accelerate market growth shortly. Ribonucleic acid transcriptome analysis enables the researchers to analyze the position of genes as well as the functional patterns of a specific gene in an organism. The method assists in evaluating every transcript’s changing behavior at the development stage and assesses all the elements of a transcript, including messenger ribonucleic acid, non-coding ribonucleic acid, and micro ribonucleic acid, for identifying the transcriptional structure of genes.

The growing need for analyzing a huge number of genes to understand the gene-to-drug interactions is anticipated to enhance the application of transcriptomics technologies in discovery applications and drug development. For instance, transcriptome profiles of COVID-19 patients have been analyzed to examine the disease prognosis and management. Furthermore, increasing demand for personalized medicines is anticipated to fuel the industry growth during the forecast period. In April 2020, Caris Life Sciences announced the submission of Pre-Market Approval applications for MI Transcriptome CDx to the USFDA. It is a powerful precision medicine assay, which contains significant companion diagnostic biomarkers. On the other hand, data management in transcriptomic research and the lack of effective bioinformatics tools are some of the major challenges in the industry.

The evolution of high-throughput technologies has provided invaluable opportunities for generating holistic views of complex biological processes. Despite the considerable availability of omics data, the conversation of biological data into clinically valuable knowledge remains one of the major challenges. It is not only because of insufficient current data processing or integration methods but also for inappropriate application of existing analysis approaches. North America has been reported as the highest revenue-generating region in 2021 owing to increasing investments in pharmaceutical and biotechnology research by corporations. Asia Pacific is projected to register the fastest CAGR from 2022 to 2030 owing to the low-cost manufacturing services.

Regional Insights

North America accounted for the largest share of more than 42.85% in 2021. The growth is attributed to the rapid development of structure-based drug designs, increasing focus on transcriptomics research, and high investments in biopharmaceutical research and development. In addition, increasing investment in pharmaceutical research and drug development is the key factor that is accelerating the revenue growth of the companies in this region. However, Asia Pacific is projected to register the fastest CAGR during the forecast period. Growing investments by governments & enterprises are accelerating biotechnology research in the countries of Asia Pacific.

The Japanese government and non-government organizations are highly supportive of the growth of biotechnology research in the country and provide funds for research in the fields of medicine and life sciences. This encourages researchers to actively explore the transcriptomics space. Furthermore, increasing focus on APAC countries, owing to the low-cost manufacturing service, is expected to provide growth opportunities for the manufacturers. In addition, strategic activities, such as partnerships, will further augment the growth of this region. For instance, in January 2020, Genetron Holdings Ltd. entered into a strategic partnership agreement with Thermo Fisher Scientific to expand its precision cancer monitoring and diagnosis in China’s public hospitals.

Some of the prominent players in the RNA Analysis Market include:

• Agilent Technologies, Inc.
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• QIAGEN
• Thermo Fisher Scientific, Inc.
• Eurofins Scientific
• Merck KGaA
• Bio-Rad Laboratories, Inc.
• Pacific Bioscience of California, Inc.
• Affymetrix, Inc.
• Danaher Corp.
• Promega

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global RNA Analysis market

• Technology
  • Real Time-PCR (qPCR) Technology
  • Microarray Technology
  • Sequencing Technology
  • Others
• Product
  • Instruments
  • Kits & Reagents
    • CHO Media miRNA & siRNA
    • Reverse Transcriptases & RT-PCR
    • RNA Extraction & Purification
    • RNA Interference
    • Others
  • Services
• Application
  • Construction of RNA Expression Atlas
  • Epigenetics
  • Infectious Diseases&Pathogenesis
  • Alternative RNA Splicing
  • RNA Structure&Molecular Dynamics
  • Development &Delivery of RNA Therapeutics
  • Others
• End-use
  • Government Institutes & Academic Centers
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Hospitals & Clinics

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7592

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/